Combipatch and Application site discoloration - a phase IV clinical study of FDA data

Summary:

Application site discoloration is reported as a side effect among people who take Combipatch (estradiol; norethindrone acetate), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Synthroid, and have Hot flush.

The phase IV clinical study analyzes which people have Application site discoloration when taking Combipatch. It is created by eHealthMe based on reports of 3,544 people who have side effects when taking Combipatch from the FDA, and is updated regularly.

What is Combipatch?

Combipatch has active ingredients of estradiol; norethindrone acetate. It is often used in menopause. eHealthMe is studying from 3,599 Combipatch users. Check the latest studies of Combipatch.

What is Application site discoloration?

Application site discoloration is found to be associated with 212 drugs and 444 conditions by eHealthMe. Check the latest studies of Application site discoloration.

On Jul, 15, 2026

3,544 people reported to have side effects when taking Combipatch.
Among them, 37 people (1.04%) have Application site discoloration.

Could Combipatch cause Application site discoloration?

Among these 37 people:

How long have people been on Combipatch when they have Application site discoloration? *

What is the gender of people who have Application site discoloration when taking Combipatch? *

female: 100 %
male: 0.0 %

What is the age of people who have Application site discoloration when taking Combipatch? *

What are other drugs people take besides Combipatch? *

What are other side effects people have besides Application site discoloration? *

Application Site Erythema (redness of the skin at application site): 26 people, 70.27%
Application Site Irritation: 22 people, 59.46%
Application Site Pruritus (application site severe itching of the skin): 22 people, 59.46%
Application Site Exfoliation (application site removal of the oldest dead skin cells on the skin's outermost surface): 11 people, 29.73%
Application Site Dryness: 10 people, 27.03%
Application Site Pain: 10 people, 27.03%
Application Site Burn: 8 people, 21.62%
Application Site Vesicles (small bubble within a cell at application site): 6 people, 16.22%
Application Site Rash: 6 people, 16.22%
Application Site Scab (hard coating on the skin formed at application site): 5 people, 13.51%

What are the existing conditions these people have? *

Hot Flush (sudden feelings of heat): 8 people, 21.62%
Night Sweats (sweating in night): 2 people, 5.41%
Fatigue (feeling of tiredness): 2 people, 5.41%
Sleep Disorder: 1 person, 2.70%
Skin Irritation: 1 person, 2.70%
Nervousness: 1 person, 2.70%
Hypersensitivity: 1 person, 2.70%
Hormone Level Abnormal: 1 person, 2.70%
Depression: 1 person, 2.70%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 2.70%

* Approximation only. Some reports may have incomplete information.

Do you take Combipatch and have Application site discoloration?

- Check whether Application site discoloration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Combipatch:

Combipatch (3,599 reports)

Application site discoloration treatments and more:

Application site discoloration (4,162 reports)

How severe was Application site discoloration and when was it recovered:

Application site discoloration in Combipatch

Expand to all the drugs that have ingredients of estradiol; norethindrone acetate:

Application site discoloration and drugs with ingredients of estradiol; norethindrone acetate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Combipatch:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site discoloration:

Application site discoloration (212 drugs)

Browse all the conditions that are associated with Application site discoloration:

Application site discoloration (444 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on estradiol; norethindrone acetate (the active ingredients of Combipatch) and Combipatch (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.